RATIONALE: Exacerbations of chronic obstructive pulmonary disease (COPD) and responses to treatment are heterogeneous. OBJECTIVES: Investigate the usefulness of blood eosinophils to direct corticosteroid therapy during exacerbations. METHODS: Subjects with COPD exacerbations were entered into a randomized biomarker-directed double-blind corticosteroid versus standard therapy study. Subjects in the standard arm received prednisolone for 2 weeks, whereas in the biomarker-directed arm, prednisolone or matching placebo was given according to the blood eosinophil count biomarker. Both study groups received antibiotics. Blood eosinophils were measured in the biomarker-directed and standard therapy arms to define biomarker-positive and -negative exacerbations (blood eosinophil count > and ≤ 2%, respectively). The primary outcome was to determine noninferiority in health status using the chronic respiratory questionnaire (CRQ) and in the proportion of exacerbations associated with a treatment failure between subjects allocated to the biomarker-directed and standard therapy arms. MEASUREMENTS AND MAIN RESULTS: There were 86 and 80 exacerbations in the biomarker-directed and standard treatment groups, respectively. In the biomarker-directed group, 49% of the exacerbations were not treated with prednisolone. CRQ improvement after treatment in the standard and biomarker-directed therapy groups was similar (0.8 vs. 1.1; mean difference, 0.3; 95% confidence interval, 0.0-0.6; P = 0.05). There was a greater improvement in CRQ in biomarker-negative exacerbations given placebo compared with those given prednisolone (mean difference, 0.45; 95% confidence interval, 0.01-0.90; P = 0.04). In biomarker-negative exacerbations, treatment failures occurred in 15% given prednisolone and 2% of those given placebo (P = 0.04). CONCLUSIONS: The peripheral blood eosinophil count is a promising biomarker to direct corticosteroid therapy during COPD exacerbations, but larger studies are required.
RATIONALE: Exacerbations of chronic obstructive pulmonary disease (COPD) and responses to treatment are heterogeneous. OBJECTIVES: Investigate the usefulness of blood eosinophils to direct corticosteroid therapy during exacerbations. METHODS: Subjects with COPD exacerbations were entered into a randomized biomarker-directed double-blind corticosteroid versus standard therapy study. Subjects in the standard arm received prednisolone for 2 weeks, whereas in the biomarker-directed arm, prednisolone or matching placebo was given according to the blood eosinophil count biomarker. Both study groups received antibiotics. Blood eosinophils were measured in the biomarker-directed and standard therapy arms to define biomarker-positive and -negative exacerbations (blood eosinophil count > and ≤ 2%, respectively). The primary outcome was to determine noninferiority in health status using the chronic respiratory questionnaire (CRQ) and in the proportion of exacerbations associated with a treatment failure between subjects allocated to the biomarker-directed and standard therapy arms. MEASUREMENTS AND MAIN RESULTS: There were 86 and 80 exacerbations in the biomarker-directed and standard treatment groups, respectively. In the biomarker-directed group, 49% of the exacerbations were not treated with prednisolone. CRQ improvement after treatment in the standard and biomarker-directed therapy groups was similar (0.8 vs. 1.1; mean difference, 0.3; 95% confidence interval, 0.0-0.6; P = 0.05). There was a greater improvement in CRQ in biomarker-negative exacerbations given placebo compared with those given prednisolone (mean difference, 0.45; 95% confidence interval, 0.01-0.90; P = 0.04). In biomarker-negative exacerbations, treatment failures occurred in 15% given prednisolone and 2% of those given placebo (P = 0.04). CONCLUSIONS: The peripheral blood eosinophil count is a promising biomarker to direct corticosteroid therapy during COPD exacerbations, but larger studies are required.
Authors: M M Pizzichini; T A Popov; A Efthimiadis; P Hussack; S Evans; E Pizzichini; J Dolovich; F E Hargreave Journal: Am J Respir Crit Care Med Date: 1996-10 Impact factor: 21.405
Authors: M Saetta; A Di Stefano; P Maestrelli; G Turato; M P Ruggieri; A Roggeri; P Calcagni; C E Mapp; A Ciaccia; L M Fabbri Journal: Am J Respir Crit Care Med Date: 1994-12 Impact factor: 21.405
Authors: Peter M A Calverley; Julie A Anderson; Bartolome Celli; Gary T Ferguson; Christine Jenkins; Paul W Jones; Julie C Yates; Jørgen Vestbo Journal: N Engl J Med Date: 2007-02-22 Impact factor: 91.245
Authors: Alberto Papi; Cinzia Maria Bellettato; Fausto Braccioni; Micaela Romagnoli; Paolo Casolari; Gaetano Caramori; Leonardo M Fabbri; Sebastian L Johnston Journal: Am J Respir Crit Care Med Date: 2006-02-16 Impact factor: 21.405
Authors: E Pizzichini; M M Pizzichini; P Gibson; K Parameswaran; G J Gleich; L Berman; J Dolovich; F E Hargreave Journal: Am J Respir Crit Care Med Date: 1998-11 Impact factor: 21.405
Authors: Mona Bafadhel; Susan McKenna; Sarah Terry; Vijay Mistry; Carlene Reid; Pranabashis Haldar; Margaret McCormick; Koirobi Haldar; Tatiana Kebadze; Annelyse Duvoix; Kerstin Lindblad; Hemu Patel; Paul Rugman; Paul Dodson; Martin Jenkins; Michael Saunders; Paul Newbold; Ruth H Green; Per Venge; David A Lomas; Michael R Barer; Sebastian L Johnston; Ian D Pavord; Christopher E Brightling Journal: Am J Respir Crit Care Med Date: 2011-09-15 Impact factor: 21.405
Authors: Jeong H Yun; Andrew Lamb; Robert Chase; Dave Singh; Margaret M Parker; Aabida Saferali; Jørgen Vestbo; Ruth Tal-Singer; Peter J Castaldi; Edwin K Silverman; Craig P Hersh Journal: J Allergy Clin Immunol Date: 2018-04-28 Impact factor: 10.793
Authors: Salman H Siddiqui; Alessandro Guasconi; Jørgen Vestbo; Paul Jones; Alvar Agusti; Pierluigi Paggiaro; Jadwiga A Wedzicha; Dave Singh Journal: Am J Respir Crit Care Med Date: 2015-08-15 Impact factor: 21.405